Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
HLA class I alleles, in particular HLA-B*57, constitute the most consistent host factor determining outcomes in untreated HCV- and HIV-infection. In this prospective cohort study, we analysed the impact of HLA class I alleles on all-cause mortality in patients with HIV-, HCV- and HIV/HCV- co-infecti...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4524598?pdf=render |
| _version_ | 1819315723662524416 |
|---|---|
| author | Leona Dold Golo Ahlenstiel Eva Althausen Carolin Luda Carolynne Schwarze-Zander Christoph Boesecke Jan-Christian Wasmuth Jürgen Kurt Rockstroh Ulrich Spengler |
| author_facet | Leona Dold Golo Ahlenstiel Eva Althausen Carolin Luda Carolynne Schwarze-Zander Christoph Boesecke Jan-Christian Wasmuth Jürgen Kurt Rockstroh Ulrich Spengler |
| author_sort | Leona Dold |
| collection | DOAJ |
| description | HLA class I alleles, in particular HLA-B*57, constitute the most consistent host factor determining outcomes in untreated HCV- and HIV-infection. In this prospective cohort study, we analysed the impact of HLA class I alleles on all-cause mortality in patients with HIV-, HCV- and HIV/HCV- co-infection receiving HAART.In 2003 HLA-A and B alleles were determined and patients were prospectively followed in 3-month intervals until 2013 or death. HLA-A and B alleles were determined by strand-specific oligonucleotide hybridisation and PCR in 468 Caucasian patients with HCV- (n=120), HIV- (n=186) and HIV/HCV-infection (n=162). All patients with HIV-infection were on HAART. In each patient group, HLA class I-associated survival was analysed by Kaplan-Meier method and Cox regression analysis.At recruitment the proportion of patients carrying a HLA-B*57 allele differed between HIV- (12.9%) and HCV-infection (4.2%). Kaplan Meier analysis revealed significantly increased mortality in HLA-B*57-positive patients with HIV-infection (p=0.032) and HIV/HCV-co-infection (p=0.004), which was apparently linked to non-viral infections. Cox logistic regression analysis confirmed HLA-B*57 (p=0.001), serum gamma-glutamyltranspeptidase (p=0.003), serum bilirubin (p=0.022) and CD4 counts (p=0.041) as independent predictors of death in HIV-infected patients.Differences in the prevalence of HLA-B*57 at study entry between HIV- and HCV- infected patients may reflect immune selection in the absence of antiviral therapy. When patients were treated with HAART, however, HLA-B*57 was associated with increased mortality and risk to die from bacterial infections and sepsis, suggesting an ambiguous role of HLA-B*57 for survival in HIV/HCV infection depending on the circumstances. |
| first_indexed | 2024-12-24T10:04:39Z |
| format | Article |
| id | doaj.art-99cd1325ecea4fb2bfe7f0a77714900c |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-24T10:04:39Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-99cd1325ecea4fb2bfe7f0a77714900c2022-12-21T17:00:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013415810.1371/journal.pone.0134158Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).Leona DoldGolo AhlenstielEva AlthausenCarolin LudaCarolynne Schwarze-ZanderChristoph BoeseckeJan-Christian WasmuthJürgen Kurt RockstrohUlrich SpenglerHLA class I alleles, in particular HLA-B*57, constitute the most consistent host factor determining outcomes in untreated HCV- and HIV-infection. In this prospective cohort study, we analysed the impact of HLA class I alleles on all-cause mortality in patients with HIV-, HCV- and HIV/HCV- co-infection receiving HAART.In 2003 HLA-A and B alleles were determined and patients were prospectively followed in 3-month intervals until 2013 or death. HLA-A and B alleles were determined by strand-specific oligonucleotide hybridisation and PCR in 468 Caucasian patients with HCV- (n=120), HIV- (n=186) and HIV/HCV-infection (n=162). All patients with HIV-infection were on HAART. In each patient group, HLA class I-associated survival was analysed by Kaplan-Meier method and Cox regression analysis.At recruitment the proportion of patients carrying a HLA-B*57 allele differed between HIV- (12.9%) and HCV-infection (4.2%). Kaplan Meier analysis revealed significantly increased mortality in HLA-B*57-positive patients with HIV-infection (p=0.032) and HIV/HCV-co-infection (p=0.004), which was apparently linked to non-viral infections. Cox logistic regression analysis confirmed HLA-B*57 (p=0.001), serum gamma-glutamyltranspeptidase (p=0.003), serum bilirubin (p=0.022) and CD4 counts (p=0.041) as independent predictors of death in HIV-infected patients.Differences in the prevalence of HLA-B*57 at study entry between HIV- and HCV- infected patients may reflect immune selection in the absence of antiviral therapy. When patients were treated with HAART, however, HLA-B*57 was associated with increased mortality and risk to die from bacterial infections and sepsis, suggesting an ambiguous role of HLA-B*57 for survival in HIV/HCV infection depending on the circumstances.http://europepmc.org/articles/PMC4524598?pdf=render |
| spellingShingle | Leona Dold Golo Ahlenstiel Eva Althausen Carolin Luda Carolynne Schwarze-Zander Christoph Boesecke Jan-Christian Wasmuth Jürgen Kurt Rockstroh Ulrich Spengler Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). PLoS ONE |
| title | Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). |
| title_full | Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). |
| title_fullStr | Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). |
| title_full_unstemmed | Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). |
| title_short | Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). |
| title_sort | survival and hla b 57 in hiv hcv co infected patients on highly active antiretroviral therapy haart |
| url | http://europepmc.org/articles/PMC4524598?pdf=render |
| work_keys_str_mv | AT leonadold survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT goloahlenstiel survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT evaalthausen survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT carolinluda survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT carolynneschwarzezander survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT christophboesecke survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT janchristianwasmuth survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT jurgenkurtrockstroh survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart AT ulrichspengler survivalandhlab57inhivhcvcoinfectedpatientsonhighlyactiveantiretroviraltherapyhaart |